Abstract Background In Non-small cell lung cancer (NSCLC), an overactive epidermal
growth factor receptor (EGFR) pathway is a component of the malignant phenotype. Two …

Two small-molecule epidermal growth factor receptor tyrosine kinase inhibitors, gefitinib and
erlotinib, have been approved for the treatment of non-small-cell lung cancer. Here, we …

Molecular targeted therapies, such as the epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitors (TKIs), provide a different mechanism of action from chemotherapy and can …

Before 2009, nonsmall cell lung cancer (NSCLC) was one disease entity treated by cytotoxic
chemotherapy that provided a response rate of 20–35% and a median survival time (MST) of …

BACKGROUND:: Erlotinib is an oral tyrosine kinase inhibitor, 1026 targeting the human
epidermal receptor type 1/epidermal growth factor receptor, recently approved by the US …

Drugs that target the epidermal growth factor receptor (EGFR) have had a major impact on
the treatment of non–small cell lung cancer (NSCLC). The use of these drugs has also …

Over the past decade, a multitude of targeted agents have been explored in the treatment of
advanced non–small cell lung cancer (NSCLC). Thus far, two broad classes of agents have …

The epidermal growth factor receptor (EGFR) is a cellular transmembrane receptor with
tyrosine kinase enzymatic activity which plays a key role in human cancer. EGFR-dependent …

The epidermal growth factor receptor (EGFR) and its ligands are frequently expressed in
non-small-cell lung cancer (NSCLC). The EGFR tyrosine kinase inhibitors (TKIs) erlotinib …

Lung cancer is the leading cause of cancer-related death in the world. Prior to the era of
targeted therapy, platinum-based doublet chemotherapy was the first-line therapy of choice …